Acapatamab (AMG-160) is a Half-Life Extended (HLE) Bispecific T-cell Engager (BiTE) with domains that bind to PSMA and CD3. Acapatamab (AMG-160) exhibits Kd values of 14.8 nM for hPSMA and 22.4 nM for hCD3. Acapatamab (AMG-160) is utilized in cancer research.

PSMA (human):14.8 nM (Kd), CD3 (human):22.4 nM (Kd)

Acapatamab (AMG-160; 0-10000 pM; 48 h) induced activation in T cells and increased the expression of CD25, CD69, 4-1BB and PD-1. Under the same conditions, the effect of Acapatamab on T-cell leads to the release of dose-dependent cytokines, including IL-2, IL-4, IL-6, IL-10, IFNγ-γ and TNFα-α. In addition, Acapatamab (0-10000 pM; 48 h) Under the condition of co-culture with PBMC, PSMA positive prostate cancer cell line can be effectively lysed, and its EC 50 value is in the range of 6-42 pM.

Administered intravenously on days 16, 23, and 31 at dosages of 0.02, 0.2, and 2 mg/kg, Acapatamab demonstrated antitumor properties by inhibiting the growth of CA prostate cancer xenograft tumors in NOD/SCID mice, specifically the 22Rv-1 CRPC model.

Human

Monoclonal

Unconjugated